These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 22810805)

  • 1. Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors.
    Murakami H; Doi T; Yamamoto N; Watanabe J; Boku N; Fuse N; Yoshino T; Ohtsu A; Otani S; Shibayama K; Takubo T; Loh E
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):407-14. PubMed ID: 22810805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.
    Rosen LS; Puzanov I; Friberg G; Chan E; Hwang YC; Deng H; Gilbert J; Mahalingam D; McCaffery I; Michael SA; Mita AC; Mita MM; Mulay M; Shubhakar P; Zhu M; Sarantopoulos J
    Clin Cancer Res; 2012 Jun; 18(12):3414-27. PubMed ID: 22510349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, pharmacokinetics and antitumor activity of ganitumab, an investigational fully human monoclonal antibody to insulin-like growth factor type 1 receptor, combined with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer: a phase 1b study.
    Okusaka T; Ikeda M; Fukutomi A; Kobayashi Y; Shibayama K; Takubo T; Gansert J
    Jpn J Clin Oncol; 2014 May; 44(5):442-7. PubMed ID: 24782485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors.
    Tap WD; Demetri G; Barnette P; Desai J; Kavan P; Tozer R; Benedetto PW; Friberg G; Deng H; McCaffery I; Leitch I; Badola S; Chang S; Zhu M; Tolcher A
    J Clin Oncol; 2012 May; 30(15):1849-56. PubMed ID: 22508822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer.
    Vlahovic G; Meadows KL; Hatch AJ; Jia J; Nixon AB; Uronis HE; Morse MA; Selim MA; Crawford J; Riedel RF; Zafar SY; Howard LA; O'Neill M; Meadows JJ; Haley ST; Arrowood CC; Rushing C; Pang H; Hurwitz HI
    Oncologist; 2018 Jul; 23(7):782-790. PubMed ID: 29572245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors.
    Doi T; Murakami H; Ohtsu A; Fuse N; Yoshino T; Yamamoto N; Boku N; Onozawa Y; Hsu CP; Gorski KS; Friberg G; Kawaguchi T; Sasaki T
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):733-41. PubMed ID: 21161528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors.
    Doi T; Shitara K; Kojima T; Yoshino T; Dontabhaktuni A; Rebscher H; Tang S; Cosaert J; Ohtsu A
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1253-62. PubMed ID: 27139036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in mice.
    Moody G; Beltran PJ; Mitchell P; Cajulis E; Chung YA; Hwang D; Kendall R; Radinsky R; Cohen P; Calzone FJ
    J Endocrinol; 2014 Apr; 221(1):145-55. PubMed ID: 24492468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors.
    Strosberg JR; Chan JA; Ryan DP; Meyerhardt JA; Fuchs CS; Abrams T; Regan E; Brady R; Weber J; Campos T; Kvols LK; Kulke MH
    Endocr Relat Cancer; 2013 Jun; 20(3):383-90. PubMed ID: 23572164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epitope-specific mechanisms of IGF1R inhibition by ganitumab.
    Calzone FJ; Cajulis E; Chung YA; Tsai MM; Mitchell P; Lu J; Chen C; Sun J; Radinsky R; Kendall R; Beltran PJ
    PLoS One; 2013; 8(2):e55135. PubMed ID: 23383308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumors.
    Higano CS; Berlin J; Gordon M; LoRusso P; Tang S; Dontabhaktuni A; Schwartz JD; Cosaert J; Mehnert JM
    Invest New Drugs; 2015 Apr; 33(2):450-62. PubMed ID: 25749986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor.
    McCaffery I; Tudor Y; Deng H; Tang R; Suzuki S; Badola S; Kindler HL; Fuchs CS; Loh E; Patterson SD; Chen L; Gansert JL
    Clin Cancer Res; 2013 Aug; 19(15):4282-9. PubMed ID: 23741071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors.
    Wakui H; Yamamoto N; Nakamichi S; Tamura Y; Nokihara H; Yamada Y; Tamura T
    Cancer Chemother Pharmacol; 2014 Mar; 73(3):511-6. PubMed ID: 24442032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab.
    Tabernero J; Chawla SP; Kindler H; Reckamp K; Chiorean EG; Azad NS; Lockhart AC; Hsu CP; Baker NF; Galimi F; Beltran P; Baselga J
    Target Oncol; 2015 Mar; 10(1):65-76. PubMed ID: 24816908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.
    Gordon MS; Sweeney CS; Mendelson DS; Eckhardt SG; Anderson A; Beaupre DM; Branstetter D; Burgess TL; Coxon A; Deng H; Kaplan-Lefko P; Leitch IM; Oliner KS; Yan L; Zhu M; Gore L
    Clin Cancer Res; 2010 Jan; 16(2):699-710. PubMed ID: 20068101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and pharmacokinetics of panitumumab in Japanese patients with advanced solid tumors.
    Doi T; Ohtsu A; Tahara M; Tamura T; Shirao K; Yamada Y; Otani S; Yang BB; Ohkura M; Ohtsu T
    Int J Clin Oncol; 2009 Aug; 14(4):307-14. PubMed ID: 19705240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts.
    Fahrenholtz CD; Beltran PJ; Burnstein KL
    Mol Cancer Ther; 2013 Apr; 12(4):394-404. PubMed ID: 23348048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors.
    Mizugaki H; Yamamoto N; Murakami H; Kenmotsu H; Fujiwara Y; Ishida Y; Kawakami T; Takahashi T
    Invest New Drugs; 2016 Oct; 34(5):596-603. PubMed ID: 27363843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I escalating single-dose and weekly fixed-dose study of cetuximab pharmacokinetics in Japanese patients with solid tumors.
    Shirao K; Yoshino T; Boku N; Kato K; Hamaguchi T; Yasui H; Yamamoto N; Tanigawara Y; Nolting A; Yoshino S
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):557-64. PubMed ID: 19169687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors.
    von Mehren M; Britten CD; Pieslor P; Saville W; Vassos A; Harris S; Galluppi GR; Darif M; Wainberg ZA; Cohen RB; Leong S
    Invest New Drugs; 2014 Jun; 32(3):518-25. PubMed ID: 24458261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.